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Traditional strategies for editing the genome of E. coli and of other bacteria rely on two-step methods 
that insert a selectable marker and then remove the same marker in a subsequent step.  Removal of the 
marker can leave scar sites that create chromosomal instability.  The no-SCAR system, which is described 
in depth here, enables marker-free and scarless genome modifications including point mutations, 
deletions, and insertions.  This technique enables iterative metabolic engineering in E. coli for a variety 
of applications.  In addition, essential genes can be modified without the need to express them from a 
plasmid.  According to our analysis, this is the fastest method for making multiple scarless chromosomal 
mutations.   
Abstract 
The discovery and development of genome editing systems that leverage the site-specific DNA 
endonuclease system CRISPR/Cas9 has fundamentally changed the ease and speed of genome editing in 
many organisms.  In eukaryotes, the CRISPR/Cas9 system utilizes a “guide” RNA to enable the Cas9 
nuclease to make a double strand break at a particular genome locus, which is repaired by non-
homologous end joining (NHEJ) repair enzymes, often generating random mutations in the process.  A 
specific alteration of the target genome can also be generated by supplying a DNA template in vivo with 
a desired mutation, which is incorporated by homology directed repair.  However, E. coli, lacks robust 
systems for double-strand break repair.  Thus, in contrast to eukaryotes, targeting E. coli chromosomal 
DNA with Cas9 causes cell death.  However, Cas9-mediated killing of bacteria can be exploited to select 
against cells with a specified genotype within a mixed population.  In combination with the well-
described λ-Red system for recombination in E. coli, we created a highly efficient system for marker-free 
and scarless genome editing.   This unit covers all aspects of using this method, named the no-SCAR 
system, for making chromosomal mutations in E. coli.  The method consists of four basic protocols that 
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comprise the system, including; design of donor DNA for recombineering, identification of target sites, 
cloning of sgRNA for targeted counterselection, and the experimental protocol to perform genome 
editing.   
Keywords: genome editing, gene deletions, λ-Red, metabolic engineering, CRISPR/Cas9, Escherichia coli 
 
Introduction 
 The ability to edit genomic DNA in vivo is important for many fields.  Traditional methods for 
genome manipulations in E. coli rely on the insertion of selectable markers, most often antibiotic 
resistance genes, to enrich for the mutants while preventing growth of wild-type cells (Datsenko and 
Wanner, 2000).  While this method is efficient, a major drawback is that the selectable marker must be 
removed in a second editing step.  An alternative strategy for making genomic mutations relies on the 
incorporation of DNA oligonucleotides (oligos) at the replication fork, known as oligo recombineering 
(Ellis et al., 2001).  Since there are no selectable makers used, it is often necessary to screen hundreds or 
thousands of colonies to identify cells that possess the desired mutations. 
 CRISPR/Cas9 is an RNA-guided DNA endonuclease that causes a double-strand break (DSB) at a 
targeted genomic location, known as the protospacer (Jinek et al., 2012).  The well-studied 
Streptococcus pyogenes Cas9 requires a protospacer adjacent motif (PAM) of NGG on the 3’ side of the 
target.  Provided that the PAM site is present, any genomic location can be targeted by altering the 
cognate DNA sequence that encodes the single guide RNA (sgRNA).  The sgRNA transcript interacts with 
Cas9 in-vivo to provide targeting specificity.  Mismatches between the sgRNA and genomic target 
location within 12-bp of PAM site, known as the seed region, or within the PAM site itself, are generally 
not tolerated and abolish Cas9 activity (Jiang et al., 2013; Jinek et al., 2012).  Thus, Cas9 can distinguish 
between genotypic populations that differ by as little as a single base pair. 
4 
 
By combining oligo recombination with CRISPR/Cas9, cells that possess a targeted mutation can 
be enriched from a mixed population by inducing DSB in cells that did not undergo recombination (Jiang 
et al., 2013).  In E. coli, this method required the λ-phage “Red” recombination system (λ-Red) to enable 
efficient genome integration of donor DNA.  The λ-Red system facilitates genomic integration of both 
single stranded DNA (ssDNA) and double stranded DNA (dsDNA) at the replication fork of growing cells 
(Maresca et al., 2010; Mosberg et al., 2010).  Using this concept of counterselection against wild-type 
cells, we developed a plasmid-based system to edit the genome of E. coli, and demonstrated the ability 
to make point mutations, deletions, and insertions in a single step with regard to the genome 
manipulation (Figure 1) (Reisch and Prather, 2015).  In practice, this system has been used to create 
point mutations, replace ribosome binding sites and promoters, insert degradation and epitope tags, 
and delete whole genes.  Deletion of the host mismatch repair system is not required for making point 
mutations with a high efficiency.  Both plasmids that comprise the system can be cured efficiently, 
resulting in host strains that are both plasmid-free and scar-free.  Curing of the target-encoding plasmid 
enables the system to be used iteratively so that many chromosomal mutations can be made in a single 
cell line.  Here, we detail the steps required to design and perform genome editing in E. coli.  The 
workflow, outlined in Figure 2, consists of four basic protocols that describe the design of DNA for 
recombineering, design of target sites for Cas9 counterselection, cloning of targets into the pKDsgRNA 
plasmid, and genome editing.   
 
Basic Protocol 1 
Title: Design of donor DNA for recombineering 
Genome editing techniques facilitated by λ-Red that use oligos as the DNA donor have been well 
established in literature (Ellis et al., 2001; Costantino and Court, 2003; Wang et al., 2009; Wang and 
Church, 2011).  Several important oligo design considerations have been identified that can increase the 
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efficiency of recombineering, including; length of oligonucleotide, addition of phosphorothioate bonds, 
reducing oligo secondary structure, and targeting the lagging strand of genomic DNA.  In basic protocol 
1, the steps required to design oligos for recombineering with the no-SCAR system are described.  Web-
based computational tools such as MODEST or MERLIN are available to aid in the design of oligos and 
may be useful to check manual designs or for large-scale experiments, although they are not described 
here (Bonde et al., 2014; Quintin et al., 2016).   
The design of recombineering templates and sgRNAs that target the unmodified target (basic 
protocol 2) are presented separately.  However, it is imperative that each be performed with the other 
in mind to ensure that a PAM site is present within 15 bp of the desired mutation.  While we have 
successfully made mutants that have only one bp change, in some cases a single bp change in the 12 bp 
seed region of the sgRNA target may not be sufficient to disrupt cutting.  Consequently, additional 
mutations may be useful in order to disrupt Cas9 targeting.  An added advantage of creating several 
mismatches within a small window prevents methyl directed mismatch repair (Sawitzke et al., 2011).  
Also, in the rare instance where there is no PAM site within 15 bp of the desired mutation, silent 
mutations can be added near the PAM site to disrupt cas9 targeting. 
    
Materials  
DNA sequence of target regions.   
A plasmid Editor (http://biologylabs.utah.edu/jorgensen/wayned/ape/) and Benchling.com are two free 
and easy to use programs for DNA editing. 
DNA editing program such as benchling.com or A Plasmid Editor  
 
1. Obtain the DNA sequence that is up- and down-stream of the mutation loci and paste into a DNA 
editing program.   
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2. Design the desired DNA sequence by inserting point mutations, removing DNA sequence, or 
inserting DNA sequence, to create a template that is identical to the genotype desired.   
When creating point mutations, incorporate a C:C mismatch to evade mismatch repair in E. 
coli (Costantino and Court, 2003).  Alternatively, as shown in Figure 3, create additional 
mismatches that result in at least three mutations within 4 bp of the desired mutation, which 
also evades the mismatch repair system (Sawitzke et al., 2011).   
Gene deletions of several hundred bp or less are very efficient.  Larger deletions, up to 62 kbp 
have been demonstrated, but the efficiency decreases with increased size (Wang et al., 
2009).  Likewise, insertions of up to several hundred base pairs are also efficient, while 
insertions of several kbp are possible, they are much less efficient. 
3. Select about 80 bp of sequence that spans the desired mutations and copy the sequence that 
corresponds to the lagging strand in E. coli.     
 Use the following guide to ensure that the lagging strand is targeted; 
- If the target is on replichore 1 (>3923998 or <1588774) then the oligo sequence should be 
complementary sequence to the (+) strand sequence 
- If the target is on replichore 2 (> 1588774 and < 3923998) then the oligo sequence should be 
the same sequence as the (+) strand sequence  
For example, the rpsL gene is located on replichore 2 at 3.47 mbp and has its coding sequence on 
the negative strand.  Thus, to target the lagging strand, the oligo must be complementary to the 
coding sequence.   
4. Check the secondary structure of the oligonucleotide with mfold 
(http://unafold.rna.albany.edu/?q=mfold/DNA-Folding-Form) using the default parameters.   
5. If the delta G is less than -12.5 kcal mol-1 then the oligo should be redesigned to decrease the 
secondary structure.  The oligo can be shifted upstream or downstream so that the mutation is no 
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longer in the middle of the oligo, though at least 15 bp should be kept between the mutation and 
the end of the oligo.    
6. Add 2-4 phosphorothioate bonds at the 5’ end of the oligo, indicated by * for both Integrated DNA 
Technologies (IDT, Coralville IA) and Sigma-Aldrich (St. Louis, MO).  
7. Order the oligonucleotide from your preferred supplier.  Oligos from both IDT and Sigma-Aldrich 
have been successfully used. 
Standard desalting is adequate for purification and the minimum synthesis scale for an 80mer is 
sufficient.   
Recombineering transformations that yield selectable mutations in the absence of Cas9 
targeting may be useful positive controls for recombination.  The rpsL mutation oligo designed in 
Figures 3 and 4 yields cells that are resistant to 50 mg L-1 streptomycin.  However, the strepR 
phenotype is recessive, and chromosomal copies must be fully segregated to show the strepr 
phenotype.  Thus prolonged recovery of about 5 hours is recommended.     
 
Alternate Protocol 1 - Design of double stranded DNA (dsDNA) for recombineering 
Oligos are generally considered to be the most efficient DNA donor for recombineering.  However, the 
length of homology and size of DNA insertions is inherently limited due to the size constraints of the 
oligo itself.  Oligos over 90 bp can be synthesized, but the cost increases significantly while quality 
decreases.  In addition, strong secondary structure is more likely with very long oligos, which may result 
in decreased efficiency of incorporation.  This problem can be overcome by instead using dsDNA as the 
DNA donor.  Within the last few years the cost and delivery time of custom made dsDNA fragments has 
decreased significantly, specifically with the availability of gBlocks from IDT and DNA strings from 
Thermo-Fisher (Waltham, MA).  DNA fragments of 500 bp can be designed de novo, with longer up- and 
downstream homology than possible using oligos.  The longer homology arms increase the efficiency of 
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recombination, possibly negating the decrease in efficiency that results from using dsDNA as compared 
to ssDNA.  Thus, for inserting sequence tags, modifying the 5’ untranslated region, inserting multiple 
point mutations into a single locus, amongst other applications, we recommend synthesizing dsDNA 
fragments with 100-200 bp of homology up- and downstream of the target site.   
Materials 
DNA sequence of targeted regions 
DNA viewing program and internet access 
High fidelity DNA polymerase 
 
Additional material and reagents for PCR amplification (UNIT 15.1) and purification of DNA (UNIT 2.1A). 
 
1. Obtain the DNA sequence of the site of interest, including about 200 bp of up- and downstream 
sequence.   
2. Design the insertion, deletion, or mutations.   
3. Copy the DNA sequence including 100-200 bp of homology on both sides of the editing location 
and order dsDNA from IDT, Thermo-Fisher, or another preferred source. 
4. Design and order oligos to PCR amplify the entire construct ordered above.   
The amount of linear dsDNA provided from synthesis typically ranges from 250 ng – 1 
µg.  PCR amplification of the construct ensures sufficient quantities of DNA for 
recombineering (see step 5).  To further increase efficiency of recombineering, the oligo 
which corresponds to the lagging strand can have phosphorothioate bonds added to the 
5’ end, though this is generally not required.  Only the lagging strand should be modified 
with phosphorothioate bonds, do not add phosphorothioates to the oligo corresponding 
to the leading strand. 
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5. PCR amplify the synthesized linear DNA using a high fidelity DNA polymerase.      
The reaction volume can be adjusted in this step.  There is no set amount of dsDNA 
recommended for transformation.  Anywhere from 100 ng to several µg may be used.  In 
general, more DNA is better, as long as salts or other contaminants are not present 
which will interfere with the electroporation in basic protocol 4.    
6. Purify the PCR product using a spin column or ethanol precipitation (UNIT 2.1A). 
7. Elute or re-suspend the DNA in dH2O so that the concentration is 100-500 ng µL-1 and save for 
use in basic protocol 4. 
 
Basic Protocol 2 – Identification and design of sgRNA targets 
Cas9 target specificity is determined by the 20 bp sgRNA sequence, which is encoded by a cognate 20 bp 
DNA sequence on plasmid pKDsgRNA-xxx.  This plasmid is designed so that the transcriptional start site 
of the Ptet promoter is the first bp of the sgRNA target sequence.  Modifying this 20 bp sequence, a 
process termed retargeting, is performed using ligation independent CPEC cloning or round the horn 
cloning with ligation (Quan and Tian, 2011; Ochman et al., 1988).  The identification of Cas9 target sites 
and the design of the sgRNA may initially seem complicated, but it is relatively easy and scalable using 
the plasmids and methods described here.  Design mistakes are common, time consuming, and 
frustrating, and we hope to limit such mistakes with this protocol.  To find an appropriate target, first 
identify a NGG PAM site within 15 bp, and on the 3’ side, of the desired mutation or deletion.  The PAM 
site can be on either strand, though the protospacer must remain on the 5’ side of the PAM (5’-N20NGG-
3’, Figure 4).  Here, the steps required for identification of targets, the design of sgRNA, and checking for 
off-target potential are detailed.  
Materials 
DNA sequence of target regions.   
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DNA viewing program. 
 
1. Use the wild-type DNA sequence obtained in basic protocol 1 and identify all NGG (or CCN) PAM 
sites. 
In the rpsL sequence shown in Figure 4, there are 8 NGG PAM sites.  Seven sites are on 
the bottom strand and one is on the top strand. 
2. Select a PAM site that is within 15 bp of the mutation site and oriented so that the mutation 
designed in basic protocol 1 disrupts sgRNA binding by altering the PAM site or the 12 bp seed 
region on the 5’ side of the PAM site.  If the PAM site is on the top strand, then the 12 bp on the 
5’ side (upstream) must be modified to disrupt Cas9 targeting.  If you are looking at the top 
strand, but the PAM site is on the bottom strand (CCN on the top strand), then the 12 bp to the 
3’ side (downstream) of the CCN must be modified.    
In the rpsL example in Figure 4, there are four PAM sites within 15 bp of the point 
mutation, but only two are positioned on the correct side of the PAM site.  PAM sites 4 
and 5 are within 15 bp of the mutation site, but they are upstream of the target and 
mutations to alter the highlighted lysine residue will not disrupt the target site.  PAM 
sites 6 and 7, are located on the correct side of the site so that mutations will disrupt 
sgRNA binding. 
Ideally, the target site should be between 40-60% GC and should not be <20% or >80% 
GC.  However, the characteristics that define a good target are still poorly understood 
and have not been investigated in E. coli.  Thus, it is likely that targets with GC content 
that fall outside of the optimum will still function. 
3. If the PAM site is on the top strand, copy the 20 bp DNA sequence that is immediately 5’ of the 
PAM.  If you are looking at the top strand, but the PAM site is on the bottom strand (CCN on the 
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top strand), copy the reverse complement of the 20 bp following of the PAM.  This sequence is 
the target site and a part of the sgRNA-target-F primer used for retargeting the sgRNA 
Examples of sgRNA design for PAM sites on both strands are shown in Figure 4.  
However, the 20 bp target sequence for the top strand PAM (site #3) should not be used 
since the target sequence is not within 15 bp of the mutation. 
4. Add the sequence gttttagagctagaaatagcaag to the 3’ end of the target sequence 
identified in step 3 to make sgRNA-target-F.   
5. Take the reverse complement of the target sequence obtained in step 3 and add the sequence 
gtgctcagtatctctatcactga to the 3’ end to make primer sgRNA-target-R.  Order primers 
from a preferred supplier.  Standard desalting and synthesis on the smallest scale available are 
sufficient.   
Find potential off-target sites 
6. Navigate to the website for “Cas-OFFinder” at http://www.rgenome.net/cas-offinder (Bae et al., 
2014). 
7. Select the PAM Type: SpCas9: 5’-NRG 
The S. pyogenes Cas9 also has activity with NAG PAM sites, though it is generally weaker 
than NGG.  Checking for off-target sites using the NRG PAM will identify both NGG and 
NAG sites for  potential off-targeting that could decrease efficiency of genome editing.  
However, we recommend only using NGG PAM site when identifying targets since the 
activity is higher.   
8. Select the target genome; from the dropdown menu select “others” and then select “Escherichia 
coli (K-12, MG1655). 
9. Paste the 20 bp target designed above into query sequence box.   
10. From the dropdown menu for “Mismatch Number”, select 3, and submit. 
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The “mismatch”, “RNA bulge”, and “DNA bulge” options can be modified to make the 
search conditions more or less stringent.  Generally, we only ensure that there are no 
exact matches in the 12 bp seed region.  Strong off-target effects in E. coli should result 
in cell death, and consequently will not be observed.  Though, they must be avoided 
because a DSB at a second site will kill cells even if the targeted site has been mutated.  
Weak off-target sites will most likely be repaired by homology directed repair from uncut 
copies of the chromosome and consequently are not a concern with this method. 
11. The results are listed in order of genomic location.  Visually inspect the results to ensure that 
there is only one exact match to the 12 bp seed region.  The target site designed above should 
be the only exact match, if there are additional exact matches then another target site should be 
chosen.  You may also consider moving or redesigning the mutation site. 
The likelihood of finding exact matches of the 12 bp seed region are very low within 
protein coding regions.  Intergenic regions have a higher likelihood, but are still very 
rare. 
 
Alternate Protocol 2 – sgRNA target identification using DNA2.0 
Automated design software that can identify target sites and check for potential off-target sites are 
available.  However, bacterial genomes are rarely included in these packages.  One easy to use design 
package that includes the E. coli K12 genome is provided on the website of DNA synthesis company 
DNA2.0 (Newark, CA) and may be useful for identifying good targets or checking manually designed 
targets.   
 
Materials 
DNA sequence of target regions.   
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DNA viewing program and internet access. 
 
Target identification and sgRNA design using DNA2.0 
1. Navigate to https://www.dna20.com/products/crispr and select “CRISPR gRNA design tool”.    
2. From the pulldown menu “species” select Escherichia coli K12 MG1655, PAM: NGG, and wild-
type Cas9. 
3. Input your target gene by entering either: gene name, genomic coordinates, or a user provided 
sequence. 
Entering a user provided sequence enables targeting heterologous genes and checking 
the E. coli chromosome for off target sites.   
Available PAM sites and targets are ranked based on predicted off targeting.  Scores of 
100 have very little likelihood of having off-target affects.   
4. Download or copy the target sites that are within 15 bp of mutation designed in basic protocol 1 
and orientated such that the mutation will disrupt Cas9 binding (basic protocol 2 and Figure 4).    
To disrupt Cas9 binding, the mutations must be located within the sequence 5’-N12NGG-
3’. 
5. To design the pKDsgRNA-target-F primer required for sgRNA cloning, add the sequence 
“gttttagagctagaaatagcaag” to the 3’ end of the sequence obtained from the DNA2.0 
output.   
6. To design the pKDsgRNA-target-R primer, take the reverse complement of the target site from 
step 5 and add “gtgctcagtatctctatcactga” to the 3’ end of the sequence. 
7. Order primers from preferred supplier.  Standard desalting and synthesis on the smallest scale 
available are sufficient.    
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Basic Protocol 3 - Target cloning by circular polymerase extension cloning CPEC 
The target site identified in basic protocol 2 must be cloned into the pKDsgRNA so that Cas9 will target 
the cognate genomic location.  The DNA that encodes the sgRNA sequence is not targeted because it 
lacks a PAM site.  One easy method to incorporate the 20 bp target is through the ligation independent 
cloning technique known as circular polymerase extension cloning (CPEC), shown in Figure 5 (Quan and 
Tian, 2011).  CPEC cloning uses linear DNA fragments that are produced by PCR and possess short 
overlapping sequences on both ends.  These overlapping regions, the sgRNA sequence in this case, can 
be modified by incorporating changes into the primers used for PCR amplification.  The linear DNA 
pieces are then assembled by performing additional thermal cycling with DNA polymerase.  In basic 
protocol 3, the details of changing the sgRNA target are described.   
 
Materials  
Primer gamR– tttataacctccttagagctcga 
Target specific primers (sgRNA-target-F and sgRNA-target-R) 
Primer CPEC2F – cggcgtcacactttgctat 
pKDsgRNA-xxx (Addgene #62654 or #62656) for PCR template 
Competent E. coli for cloning (UNIT 1.8) 
DpnI Restriction Enzyme  
0.8% agarose gel for electrophoresis 
Gel purification columns and reagents  
Super Optimal Broth (SOB) 
Super Optimal Broth with catabolite repression (SOC) (UNIT 1.8) 
LB broth and agar plates with 50 mg L-1 spectinomycin (UNIT 1.1) 
Taq DNA polymerase 
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pKDseq5 – cagtgaatgggggtaaatgg 
sgrnaR – gcctgcagtctagactcgag 
sgrnaA – agctttcgctaaggatgattt 
 
Additional reagents and equipment for agarose gel electrophoresis (Unit 2.5a), purification of DNA from 
agarose gels (UNIT 2.6), PCR amplification (Unit 15.1), Media Preparation and Bacteriological Tools (UNIT 
1.1), Transformation of E. coli (UNIT 1.8), DNA sequence analysis (Chapter 7) 
 
1. Obtain the four primers required for cloning new sgRNA targets by CPEC.  Primers CPEC2F and 
gamR are used for all CPEC retargeting reactions.  Primer pKDsgRNA-target-F and pKDsgRNA-
target-R were designed in basic protocol 2. 
2. Use any pKDsgRNA-xxx plasmid as DNA template and setup two 25 µL PCR reactions (primers 
gamR and pKDsgRNA-target-F) and (primers pKDsgRNA-target-R and CPEC2F) using a high 
fidelity DNA polymerase.  The protocol below is recommended for Q5 or Phusion polymerase 
from New England Biolabs (NEB, Ipswich MA).  
1 cycle -  98° C for 2:00 
30 cycles -  98° C for 8 seconds 
64° C (-0.2/cycle) for 8 seconds 
72° C for 3 minutes 
3. DpnI digest the template by adding 5 units per 25 µL directly to the reaction tube and incubate 
at 37° C for at least 15 minutes.   
4. Run the PCR on a 0.8% agarose gel and excise the bands at 3 and 4 kb, respectively.  Gel purify 
the PCR products and elute in a minimum amount of dH2O. 
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Micro volume spin columns enable elution in as little as 6 µL and are available from 
Zymo Research (Irvine CA, Catalog #D4003) or Epoch Biosciences (Sugar Land TX, 
Catalog #3010-250) 
5. Perform CPEC cloning by mixing the PCR products together in a single tube and setup a PCR 
reaction using a high fidelity DNA polymerase.  The PCR product from the last step will serve as 
both DNA template and primers, do not add additional template or primers.    
6. Cycle the reaction as follows. 
1 cycle -  98° C for 2 minutes 
15 Cycles -  98° C for 8 seconds 
57° C for 15 seconds 
72° C for 3 minutes 
7. Transform 5 µL of the PCR reaction into chemically competent E. coli, recover in 500 µL of SOC 
for at least one hour at 30° C, plate 200 µL on LB with 50 mg L-1 spectinomycin, and incubate at 
30° C.   
The clones grow somewhat slowly and may take 18-20 hours to appear.   
Confirm the sgRNA was retargeted by colony PCR and DNA sequencing. 
8. Pick an isolated colony with a sterile pipette tip and suspend in 100 µL of sterile dH2O.   
9. Transfer 10 µL of the cell suspension to a PCR tube and add 10 µL of 2X OneTaq master mix 
(NEB) with 0.5 µM primers pKDseq5 and sgRNAR.   
The OneTaq master mix works well and simplifies workflow, but any Taq polymerase 
should be sufficient.   
10. PCR amplify. The parameters below are designed for OneTaq DNA polymerase from NEB. 
1 cycle – 95° C for 2 min 
30 cycles –  95° C for 15 seconds 
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57° C for 15 seconds 
68° C for 1 min 
11. Sequence the product using the primer sgrnaA. 
In our experience the low copy number of the pKDsgRNA plasmid makes sequencing 
directly from the plasmid unreliable.  Sequencing the PCR product as described here 
gives better results.   
12. Recover the clones by in LB liquid or agar with 50 mg mL-1 spectinomycin 
E. coli should not be left in H20 for longer than a few hours since cell viability decreases 
over time.   
   
Alternate protocol 3 – Round the horn cloning 
Round the horn cloning is a form of inverse PCR that can be used to perform plasmid mutagenesis by 
incorporating mutations into PCR primers (Ochman et al., 1988).  One set of primers is used to amplify 
an entire plasmid followed by ligation to circularize the linear DNA (Figure 5).  For re-targeting, the 
entire 20 bp target sequence is changed by incorporating these 20 bp onto the 3’ end of the primer.  
This method is generally preferred since only one PCR reaction is needed.  In addition, only one unique 
primer is required for each target since the same promoter specific primer, PtetR, can be used in every 
re-targeting reaction.  Both Q5 polymerase (NEB) and KOD polymerase (EMD-Millipore, Billerica MA) 
have been successfully used for amplification of the approximately 7 kb pKDsgRNA backbone. 
Materials  
Primers – sgRNA-target-F and PtetR (PO4-gtgctcagtatctctatcactga) 
High fidelity DNA polymerase 
0.8% agarose gel for electrophoresis 




Additional reagents and equipment for agarose gel electrophoresis (Unit 2.5a), ligation of DNA 
fragments (UNIT 3.16), PCR amplification (Unit 15.1), Transformation of E. coli (UNIT 1.8), DNA sequence 
analysis (Chapter 7) 
 
1. Obtain the two primers required for round the horn cloning of new sgRNA targets. 
The first primer is sgRNA-target-F described in basic protocol 3.  The second primer 
(PtetR) is the reverse complement of the 20 bp upstream of the Ptet promoter +1 site.  
The PtetR primer should be ordered with a 5’ phosphorylation.   
2. Setup a 10-20 µL PCR reaction with a high fidelity polymerase and any pKDsgRNA-xxx plasmid as 
template.   
1 cycle -  98° C for 2:00 
30 cycles -  98° C for 8 seconds 
64° C (-0.2/cycle) for 8 seconds 
72° C for 3 minutes 
3. DpnI digest the template by adding 2 units per 10 µL to the PCR reaction and incubate at 37° C 
for at least 15 minutes. 
4. Check the PCR product by running on a 0.8% agarose gel and ensure that the product is a single 
band at the correct size of 7 kb.   
5. Setup a 10-20 µL ligation reaction with the PCR product at 1:20 dilution.   
a. We typically use a 20 µL reaction setup as follows; 16.5 µL dH20, 2 µL 10X ligase buffer, 
0.5 µL T4 ligase, and 1 µL of PCR reaction.   
6. Incubate for at least 1 hour at room temperature. 
7. Transform 5 µL into chemically competent E. coli and recover at 30° C in SOC for at least 1 hour.   
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8. Plate 200 µL onto LB agar with 50 mg L-1 spectinomycin and incubate at 30° C overnight.   
9. Screen the colonies by PCR as described in basic protocol 3.     
 
Basic Protocol 4 - Recombineering and Cas9 counterselection in E. coli.  
After the recombineering DNA and counterselection plasmids have been designed and constructed, 
performing scarless Cas9 assisted recombineering is straightforward.  The first iteration of the method, 
shown in Figure 1, requires the sequential transformation of plasmids pCas9cr4 and pKDsgRNA-xxx, 
followed by transformation of donor DNA.  Here we detail the experimental steps required for 
transformation of the host strain, screening potential recombinants, and finally plasmid curing.   
 
Materials 
pCas9cr4 (Addgene #62655) 
E. coli host strain 
SOB; with 30 mg L-1 chloramphenicol, with 30 mg L-1 chloramphenicol and 50 mg L-1 spectinomycin 
pKDsgRNA-xxx (made in basic protocol 3) 
Sterile 20% L-arabinose 
Sterile 20% Glycerol – 1.5% Mannitol Solution (Chilled) 
Sterile dH2O (Chilled) 
Oligonucleotides or dsDNA donor 
Electroporation cuvettes 
Electroporator 
Primers for DNA sequencing or allele specific PCR 




LB agar plates (UNIT 1.1) containing;  
 30 mg L-1 chloramphenicol 
30 mg L-1 chloramphenicol and 50 mg L-1 spectinomycin 
30 mg L-1 chloramphenicol, 50 mg L-1 spectinomycin, and 100 µg L-1 aTc 
50 mg L-1 spectinomycin and 100 µg L-1 aTc 
 
Additional reagents and equipment for miniprep of plasmid DNA (UNIT 1.6), agarose gel electrophoresis 
(UNIT 2.5a), PCR amplification (UNIT 15.1), Transformation of E. coli (UNIT 1.8), DNA sequence analysis 
(Chapter 7) 
 
1. Obtain the E. coli strain with plasmid pCas9cr4 from Addgene (#62655), grow overnight at 37° C 
in LB with 30 µg L-1 chloramphenicol, and miniprep the pCas9cr4 plasmid. 
2. Transform pCas9cr4 into the desired host strain by chemical transformation or electroporation 
(UNIT 1.8).    
3. Recover in SOC for one hour, plate 200 µL on LB with 30 µg L-1 chloramphenicol, and incubate at 
37° C.   
4. The next day, pick 1-3 colonies and prepare competent cells suitable for plasmid transformation 
(UNIT 1.8).   
5. Transform the pKDsgRNA-xxx targeting vector made in basic protocol 2.  Recover in SOC for at 
least one hour and plate 200 µL on LB with 30 mg L-1 chloramphenicol, 50 mg L-1 spectinomycin, 
and incubate at 30° C overnight.   
At this point you can also plate on LB with 30 mg L-1 chloramphenicol, 50 mg L-1 
spectinomycin, and 100 µg L-1 aTc to test for targeting efficiency.  Depending on 
transformation efficiency, make 3-5 tenfold dilutions and spot 8 µL of each dilution onto 
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the plates with or without aTc and incubate overnight at 30° C.  If the cell killing is 
efficient, there will be no colonies on the aTc plate.  At a minimum, there should be a 
tenfold change in colony counts between the induced and un-induced plates.  If there is 
no difference in colony counts, then the targeting plasmid should be sequence verified.  If 
the plasmid is correct, select and test a new target.  Targets that have no killing are very 
rare in our experience. 
6. Take 1-3 colonies and inoculate into 4 mL of SOB with 30 mg L-1 chloramphenicol and 50 mg L-1 
spectinomycin.  Incubate at 30° C until the OD600 reaches 0.4-0.5, about 4-6 hours.  Induce λ-Red 
by addition of L-arabinose to 0.2% and incubate for 15 minutes.   
7. Place the culture on ice for at least 5 minutes to quickly chill the cells.  
8. Centrifuge at 3,000 x g for 10 minutes to pellet the cells and then remove the supernatant by 
aspiration.   
9. Resuspend the cells in 1 mL of ice cold water and then gently pipette 1 mL of glycerol-mannitol 
solution to the bottom of the tube so that a density layer is formed with the cells layered above 
the glycerol mannitol solution. 
Any method can be used to make electrocompetent cells, though we prefer the glycerol-
mannitol density step method because it is quick and yields cells with consistent time 
constants upon electroporation (Warren, 2011). 
10. Centrifuge the cells at 3,000 x g for 10 minutes and aspirate the supernatant by first removing 
the top layer, and then the bottom layer of liquid.   
11. Resuspend the cells in 400 µL of glycerol mannitol solution and use immediately or freeze at -80° 
C for later use.  
The volumes given here can be scaled accordingly.  For oligo recombineering point 
mutations and deletions, the volumes given above yield sufficient a number of colonies.     
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Linear DNA Transformation 
12. Take 50 µL of the competent cells prepared above and add donor DNA to a concentration of 2 
µM for oligos or add 100 ng-1 µg for dsDNA.  Mix gently and transfer to a 1 mm electroporation 
cuvette on ice. 
13. Pulse using standard settings for a 1 mm cuvette of 1.8 kV, 200 Ω, and 25mF. 
The time constant should be greater than 5 µs, though lower time constants may also 
yield successful recombinants.   
14. Immediately recover in 1 mL of room temperature SOC and incubate with mixing at 30° C.   
A good control at this point is the transformation of an oligonucleotide that is not 
targeted by the sgRNA, and thus only cell death is expected.   
15. Perform five tenfold dilutions and spot 8 µL of each dilution onto plates with LB Cm +Spec + aTc 
and incubate at 30° C.   
If the oligo incorporation and cell killing by Cas9 counterselection are efficient, then 
about 3 orders of magnitude more colonies should be seen on the plate with the on-
target oligo, as compared to the control transformation with an off-target oligo.  Lower 
efficiency of both killing and recombination may result in similar colony counts for both 
transformations.  However, even in these cases it is often possible to identify mutants by 
screening with PCR or sequencing.   
16. Genotype the colonies on the experimental plate by Sanger sequencing (Chapter 7) or allele 
specific PCR (UNIT 9.8).   
Allele specific PCR can be used for genotyping because Taq polymerases does not have 3’ 
to 5’ exonuclease activity and is unable to extend when mismatches are present at the 3’ 
end of the primer (Newton et al., 1989).  However, we do not recommend identification 
of single bp mismatches because of the tendency of Taq polymerase to extend some 
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single bp 3’ mismatches (Huang et al., 1992).  Two to four mismatches at the 3’ are 
unlikely to extend and generally work well.      
Target plasmid (pKDsgRNA-xxx) curing.  
17. Inoculate a single colony into LB broth and incubate at 37° C for 5-24 hours. 
18. Streak for isolation on LB with 30 mg L-1 chloramphenicol plate and incubate at 42° C overnight. 
19. Patch the isolated colonies onto plates with LB only and LB with 50 mg L-1 spectinomycin and 
incubate at 30° C to test for spec sensitivity.   
The pKDsgRNA plasmid can be cured because of its temperature sensitive origin of 
replication.  While the plasmid is unable to replicate at temperatures of 37° C or greater, 
the plasmid is stable at these temperatures, thus the curing occurs through dilution of 
rapidly dividing cells.  At least one passage is generally required before cells can be 
considered plasmid free.   
20. Patched colonies that do not grow on LB with 50 mg L-1 spectinomycin have been cured of the 
pKDsgRNA-xxx plasmid and can be used for subsequent steps. 
pCas9cr4 curing  
21. Transform the pKDsgRNA-p15a plasmid into the cells by electroporation or chemical 
transformation and recover in 1 mL of SOC at 30° C for 2-3 hours.   
22. Add 100 µg L-1 of aTc to induce cas9 and the p15a targeting sgRNA. 
23. Incubate for two hours at 30° C and then plate on LB with 50 mg L-1 spectinomycin and 100 ng L-1 
aTc and incubate at 30° C overnight.   
24. Screen 10-20 colonies by patching onto LB only and LB 30 mg L-1 chloramphenicol and incubate 
at 37° C to check for the loss of chloramphenicol resistance.   
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The most common problem in the curing of the pCas9cr4 is that the cells are not cured of 
the initial pKDsgRNA plasmid.  Thus, it is important to ensure that your cells are 




The development of CRISPR/Cas9 tools has revolutionized the ability to perform targeted 
genome editing in eukaryotic cells.  DSBs can result in functional deletions because of the error-prone 
nature of the non-homologous end joining (NHEJ) repair mechanism.  NHEJ often creates small 
insertions or deletions (indels) that result in frameshift errors that disrupt gene translation.  
Alternatively, supplying a DNA repair template that has homology to the cut site allows for precise 
insertions of foreign DNA.  This technology has proven remarkably versatile in terms of host range 
within the eukaryotes. 
In bacteria, use of CRISPR/Cas9 for genome editing remains relatively uncommon (reviewed in 
Luo et al., 2016).  In contrast to eukaryotic cells, most bacterial species do not have robust systems for 
NHEJ.  Consequently, DSB does not cause indel formation and only results in cell death.  In addition, 
native bacterial recombination systems are not robust enough to incorporate DNA repair templates into 
the genome at a high enough efficiency to carry out the gene editing techniques described in this Unit.  
Therefore, in E. coli, standard methods for performing gene deletions and insertions rely on the λ-Red 
system, which is highly efficient when inserting a selectable marker onto the chromosome.  The λ-Red 
protein Beta also facilitates ssDNA recombineering, in which oligonucleotides are incorporated into the 
chromosome at the replication fork during DNA synthesis.  Oligo recombineering is very efficient, but it 
inherently does not use selectable markers, which necessitates screening of many colonies to find those 
that have incorporated the desired mutation.  Thus, it was hypothesized that combining Cas9 
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counterselection of wild-type cells with oligo recombineering could enable a DNA editing system in 
bacteria (Jiang et al., 2013; Reisch and Prather, 2015).   
The use of CRISPR/Cas9 for bacterial genome editing was first demonstrated in 2013 (Jiang et 
al., 2013).  This work demonstrated the ability to make several modifications when providing a repair 
template at the site of Cas9 cutting in the naturally recombinagenic bacteria Streptococcus pneumoniae.  
In E. coli, the work was limited to a single bp change in the rpsL gene using an oligo as donor DNA and 
recombinant expression of λ-Red.  Transformation with an oligo that conferred a streptomycinR rpsL 
mutation was found in 61% of cells that were selected by resistance to CRISPR/Cas9-mediated DSBs.  As 
a general method, however, this system was not modular because it required a strain that possessed 
genome integrated λ-Red.  Later, the same two-plasmid system used by Jiang et al. was combined with 
the commonly used λ-Red plasmid pKD46 (Datsenko and Wanner, 2000; Pyne et al., 2015).  In addition 
to oligo based recombineering, Pyne et al. demonstrated the insertion of dsDNA donors into the 
chromosome.  Notably, this work was performed at a single genomic locus, making it unclear how 
robust this method is for genome engineering projects that require editing across the genome.  Using 
similar plasmids, it was recently found that 8 of 12 targets tested in wild-type E. coli did not cause cell 
death because of inefficient DNA cutting (Cui and Bikard, 2016).    
In contrast, the no-SCAR system plasmids have shown robust ability to target many different 
genomic locations.  In fact, nine of the same targets that were used in the work by Cui and Bikard were 
tested for cell killing using the no-SCAR plasmids (Figure 6).  Cell death was consistent for most targets, 
with the exception of the eamB and treF targets designed by Cui and Bikard.  Examination of these two 
target sequences reveals that they have a very high GC content, and both have long stings of G’s.  The 
treF target has an overall GC content of 80% and 92% in the 12 bp seed region.  The eamB target has an 
overall GC content of 65% and 83% in the 12 bp seed region.  It has been observed that very high or low 
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GC content adversely affects cutting by Cas9 (Wang et al., 2014).  In addition, G-rich target sites contain 
many PAM sites, which has also been shown to negatively affect targeting (Malina et al., 2015).   
We hypothesize that the discrepancy between the 5 targets which did not function in Cui and 
Bikard but functioned with no-SCAR plasmids is simply the result of differences in cas9 expression.  The 
pCas9 plasmid used by Jiang et al., Pyne et al., and Cui and Bikard maintains the native S. pyogenes 
promoter and 5’ untranslated region to drive expression of cas9.  It is likely that the strength of this 
promoter in E. coli does not efficiently induce cas9 expression, exacerbating the fact that some target 
sites are worse than others.  In contrast, the pCas9cr4 plasmid has the well-tested Ptet promoter 
derived from the Tn10 transposon.  A second key difference is that the no-SCAR systems utilizes the 
single guide RNA construction in which the trans-activating crRNA (tracrRNA) and target specifying 
CRISPR RNA (crRNA) were fused to form a chimera, thus requiring only a single transcript (Jinek et al., 
2012).  The system used by Cui and Bikard maintained the native dual-guide RNA system where the 
tracrRNA and crRNA were expressed from the native S. pyogenes promoter.  The efficiency of these two 
different guide RNA systems has not been studied in E. coli and could contribute to the observed 
differences in cell death.  Regardless of the mechanism, the data clearly shows that the no-SCAR system 
is a more robust counter-selection tool for genome editing in E. coli.   
The data presented in Figure 6, as well as our previous work (Reisch and Prather, 2015) , was 
performed in wild-type E. coli MG1655.  This is notable because many oligo recombineering methods 
use strains that are deficient in the methyl-directed mismatch repair system due to a mutS deletion.  
Mutation efficiency is much higher in these strains because point mutations are not reverted to wild-
type.  However, it is problematic that background mutations accumulate at higher rates in a mutS 
background.  The effect of mutS on genome editing efficiency with the no-SCAR system has not been 
investigated, but we note that the system functions well with intact mutS.  The no-SCAR system has also 
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been used successfully in strain BL21 and in a recA strain of E. coli.  In BL21, the efficiency is lower than 
that observed in MG1655.  For unknown reasons, λ-Red recombination efficiency in BL21 is generally 
lower than in K-strains, and it has been noted that multiplex automated genome engineering (MAGE) 
does not work in BL21 (Raman et al., 2014).  Nevertheless, despite varying efficiencies, the no-SCAR 
system can be applied to most strains of E. coli without the need for modification.   
The no-SCAR system works very well for the introduction of point mutations into both essential 
and non-essential genes.  Deletions and short sequence insertions also work well, though the efficiency 
is generally less than that seen for point mutations.  Nonetheless, screening up to tens of colonies 
generally enables identification of the correct mutant.  Larger insertions of over 100 bp using dsDNA as 
template is also possible, though the efficiency is low and seems to vary widely depending on the size 
and location of insertion.  Overall, compared to other strategies for scarless genome editing, the no-




o Be sure that the sgRNA is targeting the wild-type genome sequence. 
o Check for similar target sequences elsewhere in the genome (Basic protocol 2) and do 
not use targets with identical matches to the 12 bp seed region and possess a NAG or 
NGG PAM site.   
o Do not include the PAM site on the sgRNA template. 
o Avoid target sites with extreme GC content. 
• Recombineering 
o  Target the lagging strand if using an oligo as DNA template. 
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o The mutation must disrupt cas9 targeting by changing the protospacer seed region or 
PAM site (5’-N12NGG-3’). 
o Do not induce λ-Red for longer than 30 minutes because the Gam protein is toxic. 
• Plasmid curing 
o Be sure that the pKDsgRNA-xxx plasmid is cured before transforming with the 
subsequent pKDsgRNA-xxx plasmid.    
 
Troubleshooting 
Problem Possible Cause Solution 
• sgRNA target cloning 
results in clones that 
possess the template 
target only 
• Template not efficiently 
removed from cloning 
reaction 
• DpnI digest the PCR products 
• Minimize the amount of 
template DNA in the re-
targeting reaction 
• sgRNA target is not 
correct 
• Mutation present in oligo or 
incorporated during PCR 
• Screen additional clones 
• No cell death after cas9 
induction 
• Improper design of sgRNA 
target 
• Be sure that target is orientated 
properly relative to the PAM 
site and that the PAM site is not 
included on the sgRNA 
• aTc has been inactivated 
• Make new plates, store in the 
dark 
• Target site does not • Identify new target 
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function (very rare) 
• Mutants not identified 
• Mutation results in a 
phenotype that makes cells 
non-viable or slow growing 
• Screen colonies that appear late 
and grow slowly 
• Poor recombination 
efficiency of the oligo 
• If possible, move the mutation 
and redesign the oligo 
• Use dsDNA with extended 
regions of homology on either 
side of the desired mutation 
• Attempting to make 
several mutations within a 
small window but mixed 
populations are found 
• The mismatch repair system 
may be responsible for 
correcting the mutations 
which are not targeted by 
Cas9 
• Screen more colonies 
• Perform the mutagenesis in 
more than one step. 
• pCas9cr4 cannot be cured 
• Cells were not cured of 
previous pKDsgRNA-xxx 
plasmid 
• Ensure that the cells do not 
grow on LB with 50 mg L-1 




Cell death by DSB.  
Targeting the chromosome with sgRNA and cas9 should result in cell death.  As seen in Figure 6, 
induction of cas9 typically results in colony counts that are 103-105 lower than un-induced cells.  The 
targets eamB and treF, which show no significant decrease in colony counts, are very rare and likely the 
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result of poor target selection.  Another factor that sometimes leads to problems with cell death is 
degradation of aTc, which is light sensitive and generally labile.  Plates should be stored in the dark at 4° 
C.  If induction with aTc does not cause cell death, freshly made plates often cures this problem.  Even 
when stored in the dark, plates older than 1 month sometimes result in poor killing. 
Recombineering and cas9 counterselection  
The efficiency of the no-SCAR system depends on the efficiency of both λ-Red facilitated 
recombination and cell killing by Cas9.  The parameters for oligo design described here should result in 
oligos that are efficient for recombination, however, we have observed that some genomic loci are more 
difficult to modify than others.  For well-designed point mutations, it is not unusual to find that all 
colonies have the correct genotype.  Modifications that are less efficient, such as insertions or large 
deletions, may require screening tens of colonies to identify one that is correct.  For difficult mutations it 
may be prudent to use dsDNA with long regions of homology.  For example, if you already have the 
mutation in one strain and are trying to move the mutation to a second strain, try to PCR amplify the 
mutation with 200-500 bp of homology on either side.  Alternatively, dsDNA can be synthesized with 
longer regions of homology as described in alternate protocol 1.   
Time Considerations 
The design of oligonucleotides for recombineering and sgRNA targets presented in basic 
protocols 1 and 2 can be performed in parallel.  In addition, for genome engineering projects that 
require several mutations, the design and cloning of sgRNA can be performed in parallel prior to 
beginning the in-vivo editing steps.  This will decrease the lag time between performing each set of 
mutations.   
The retargeting of sgRNA can be performed rapidly and in large batches.  We have cloned up to 
25 targets in one batch using round the horn cloning, described in alternate protocol 2.  The PCR, 
ligation, and transformation can easily be performed in a single day.  Generally, the clones are correct 
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and we proceed to the subsequent step before sequence verification is complete.  However, sequence 
verification is recommended because clones can contain mismatches or deletions due to errors in 
primer synthesis. 
Outside of the time required for cloning, the first iteration of the no-SCAR method can be 
performed in less than one week.  If continuing immediately with additional mutations, subsequent 
iterations can be performed in as little as 3 to 4 days, assuming the pKDsgRNA-xxx and mutation oligos 
have already been made.  As outlined previously, we argue that this is the fastest method for iterative 
genome engineering (Reisch and Prather, 2015). 
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Figure 1. Schematic of the no-SCAR system workflow. The host strain is first transformed with pCas9cr4 
and then pKDsgRNA-xxx. The pKDsgRNA plasmid possesses the λ-Red system in addition to the sgRNA 
that provides target specificity to Cas9. After induction of λ-Red, including Beta (blue ovals), the cells are 
transformed with ssDNA (or dsDNA) which can be incorporated at the replication fork of DNA synthesis. 
Expression of cas9 and sgRNA that targets wild-type DNA sequence results in DSB and cell death in the 
















Figure 3. Oligo design for recombineering of the rpsL gene in E. coli. A) The up- and downstream 
nucleotide sequence of rpsL with the site of mutation highlighted in blue. B) A single bp mutation shown 
in red causes the substitution K43R. The 80 bp of DNA sequence corresponding to the mutation oligo is 
highlighted. C) Three silent mutations are shown in red to evade the mismatch repair system. D) Final 
oligonucleotide design that includes 4 bp mismatches shown in lowercase, 4 phosphorothioate bonds at 







Figure 4. Schematic of sgRNA targeting design in the rpsL gene. A) PAM sites are highlighted in yellow 
and the site of point mutation is highlighted in blue. B) One PAM site on each strand is shown in red with 
the corresponding protospacer (sgRNA target) sequence in green and boxed. C) Primer designs for CPEC 










Figure 5. Schematic for re-targeting the pKDsgRNA plasmid by two piece CPEC or round the horn 
cloning. The new 20 bp target sequence, shown in red, is incorporated into primers P1 and P2. Primers; 












Figure 6. Fold-change in colony counts between cas9 induced and un-induced plates for the no-SCAR 
system plasmids. Cells were first transformed with pCas9cr4 and then the pKDsgRNA plasmid with each 
target indicated above. Single colonies were then suspended in water and six tenfold dilutions were 
spotted on plates with 30 mg L-1 chloramphenicol, 50 mg L-1 spectinomycin, and with or without 100 µg 
L-1 aTc. The number of colonies on plates without aTc were divided by the number of colonies with aTc 
to calculate the fold-change. The fold-change given is the average of plating three isolated colonies and 
the error bars represent the range of the same three experiments. In the manuscript by Cui and Bikard, 
targets mhpR and speA caused cell death, while the remaining seven targets did not. 
